Hologic (NASDAQ:HOLX) shares plunged ~18% in early premarket trading on Friday after the diagnostic product maker, with its Q2 FY25 results, lowered its earnings outlook, citing a potential impact from the Trump administration’s tariffs and geopolitical tensions.
Marlborough, Massachusetts-based Hologic (NASDAQ:HOLX) posted $1B in revenue for the quarter in line with Street forecasts but indicating a ~2% YoY decline as its COVID-19-related revenue plunged ~30% YoY, keeping its Diagnostics revenue at $453.6M, roughly unchanged from a year ago.
Meanwhile, the company’s breast health and surgical segments added $356.2M and $162.5M to the topline, implying a ~7% YoY drop and ~4% YoY growth, respectively.
While HOLX’s non-GAAP gross margin improved by 40 bps to ~61% mainly due to higher margins at its newly acquired Endomagnetics and Gynesonics units, the company’s adj. earnings per share remained flat at $1.03, exceeding Street forecasts.
As for the full-year outlook, Hologic (NASDAQ:HOLX) reiterated revenue guidance for 2025 at $4.05B - $4.10B in line with FactSet consensus but lowered adj. earnings per share guidance to $4.15 - $4.25 from $4.25 - $4.35 in the prior forecast, falling short of $4.26 projected by analysts.
The company’s Q3 outlook also fell short of Street forecasts as $1.04 - $1.07 of adj. earnings per share and $1.00B - $1.01B projected for the quarter missed $1.09 and $1.03B in the consensus, respectively.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.